• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173491 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
2 [" H& p" |0 b5 t* i0 M4 y2 U2 r" t

& q6 u! _/ ?  {3 G1 M, z9 U% kSub-category:
( {4 m# E  V- x: `7 h3 GMolecular Targets : a/ L, l; ]0 ^! J$ O
7 S) `" b6 U# S- c

& i; O# u! @* i3 c% @  YCategory:
' J$ V  C% K! O5 X( G0 L! CTumor Biology 4 e4 ]: w" ?, k$ ]8 g5 q. t
0 s4 d( t& e: G3 r2 x$ e; I. ~9 F

) F& s" d- w  PMeeting:
! q$ _4 A9 ?% Z2011 ASCO Annual Meeting 2 [5 J  T% w) @
; ?! \' e$ c, w1 g- T5 q# ^4 m2 d

  ], z7 a. E$ c9 DSession Type and Session Title:
6 H  }- m; d8 }" S$ n8 QPoster Discussion Session, Tumor Biology
3 Q) B8 M% B9 Q' M' e2 Y& ^+ D# S
/ z( a7 M) C! F9 y& _) {+ `
Abstract No:1 g( e9 B3 v, K0 z, d
10517
, o6 E+ @& y1 p$ d( [, c- K' s
5 k% c! }6 Y% j; G/ O# {1 `: A1 }% [; I3 E+ M& l
Citation:( @  j4 P7 J- I3 e" ^" _. M. n
J Clin Oncol 29: 2011 (suppl; abstr 10517)
8 l( F$ D/ V- G: @/ s
* n/ ]. S1 \/ D9 o3 z7 k
1 {9 m( V$ p8 Y, \9 ^  @, yAuthor(s):
, B& S& \# ]' }J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 3 O4 Y( i. q* @/ H. e% B: S5 H4 l
9 \+ \9 w2 d9 ?
, F6 _$ G' B. }& d6 k% ?6 G8 H
! p  |* b# Z, I; w1 u+ _
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.6 h8 J# a+ r8 i  @1 {3 J

% \3 D$ g$ f" g5 `" M) ]Abstract Disclosures
/ X: Z0 u+ A9 `  P* D8 @
. V! d& K+ L& S9 _Abstract:
/ o' _1 D% i2 B- l  |2 [1 l, O
: A8 v& S* h' A9 y
/ x7 B8 s* _% _$ ]$ dBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 [) x. p7 Z3 I# ^* O4 Y& M
" m" r4 e8 N8 N3 f6 U( Z
- Z2 l+ q% Q* t  ^! p3 p. r
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
6 R: z# E, w5 H$ \+ t* O- h没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
! I1 ~% d) J  d
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 - [, Z. X, J: J
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。3 [: B& j. X& D8 ?5 [- P) W
ALK一个指标医院要900多 ...
, p* H; N" l3 Z
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
4 k8 u7 a3 d( b* v* g" U/ M( a! |1 w! m3 _
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表